Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 15/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6612424 | 0.91 | ACLY (0.46) | ACLYCA2CA9ACACBACACA | |
| SCHEMBL6691572 | 0.87 | SMN1; SMN2 (0.41) | PFKFB3LMNASMN1; SMN2MCOLN3ACLY | |
| SCHEMBL6614194 | 0.87 | CYP2E1 (0.47) | PFKFB3ACLY | |
| SCHEMBL6698387 | 0.86 | PFKFB3 (0.41) | PFKFB3SMN1; SMN2ACLY | |
| SCHEMBL6612002 | 0.84 | ATM (0.45) | PFKFB3 | |
| SCHEMBL6612001 | 0.82 | PFKFB3 (0.41) | PFKFB3SMN1; SMN2ACLY | |
| SCHEMBL6611498 | 0.81 | PFKFB3 (0.38) | PFKFB3ACLYCA2CA9 | |
| SCHEMBL20899638 | 0.80 | CKS1B (0.43) | PFKFB3SMN1; SMN2ACLY | |
| SCHEMBL6613766 | 0.80 | PFKFB3 (0.37) | PFKFB3LMNASMN1; SMN2MCOLN3ACLY | |
| SCHEMBL6610958 | 0.79 | MCOLN3 (0.50) | PFKFB3LMNASMN1; SMN2MCOLN3ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004112779-A1 | NEW USE VII | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | claimed |
| EP-1461333-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2004-09-29 | — | — | EP | claimed |
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | claimed |
| WO-2003044009-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-05-30 | — | — | WO | claimed |
| WO-2004112779-A1 | NEW USE VII | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| EP-1461333-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | disclosed |
| WO-2003044009-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130279-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD3B1 | PFKFB3 2793/4885LMNA 1976/4885SMN1; SMN2 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.